Tirzepatide is administered as a once-weekly subcutaneous injection, with dosing typically initiated at 2.5 mg and increased by 2.5 mg every 4 weeks up to a maintenance dose of 5-15 mg based on tolerability and therapeutic response
Swab the stopper before the reconstitution syringe enters it, and again before each weekly dose draw
Polycythemia Vera: An increase in red blood cell mass may occur, which needs medical evaluation
If you are struggling to achieve HbA1c targets despite metformin and lifestyle modifications, tirzepatide offers substantial improvement potential
Together, you can create a personalized treatment plan
But because unexplained hypercobalaminemia has been consistently associated with an elevated risk of subsequent cancer diagnosis in large population studies, its one of those lab results worth following up on rather than hoping it goes away